Hyderabad, April 15 -- MSN Laboratories on Wednesday announced the launch of 'SEMABEST', its semaglutide brand, in the Indian market following approval from the Central Drugs Standard Control Organisation (CDSCO).
In a release, the Hyderabad-based pharmaceutical company said the product, indicated for chronic metabolic conditions including Type 2 Diabetes, is priced nearly 50 per cent lower than the innovator drug, aiming to improve affordability and patient access.
The therapy is available as a pre-filled pen for subcutaneous administration.
SEMABEST has demonstrated bioequivalence to the reference drug, supported by Phase III clinical studies showing comparable reduction in HbA1c levels, along with similar outcomes in fasting plasma gl...